Skip to main content
Premium Trial:

Request an Annual Quote

Deloitte Consulting Buys Analytics Firm Recombinant Data

NEW YORK (GenomeWeb News) – Deloitte Consulting late on Tuesday announced it has acquired Recombinant Data for an undisclosed amount.

Based in Newton, Mass., Recombinant Data provides healthcare IT solutions and research data management and analytics. Its products and services, Deloitte Consulting said, are used to advance personalized medicine, translational research — including genomics, phenomics, and proteomics — and healthcare performance management.

Its services allow academic medical centers, federal agencies, and life science firms to "conduct translational research and analyze phenomic, genomic, and biobanking data in pursing personalized and evidence-based medicine," Deloitte Consulting said. "These solutions can help clients unlock the underlying power of digital data."

The deal, Recombinant Data added, will accelerate its product development, sales, and staffing, while expanding Deloitte Consulting's footprint in Boston.

The business will be incorporated within Deloitte Consulting Innovation under the name Recombinant by Deloitte. Recombinant Data, Deloitte Consulting said, has seen "significant" year-over-year growth since its founding in 2005.

"Joining forces with Recombinant represents a bold move around innovation that will open new horizons for Deloitte in the life sciences and healthcare sectors,” Andrew Vaz, principal and chief innovation officer of Deloitte Consulting, said in a statement. "It will extend the Deloitte brand into hybrid business models in which world-class services are combined with advanced intellectual property assets."

Deloitte Consulting is a subsidiary of Deloitte.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.